Late Thrombolysis in Massive Pulmonary Thromboembolism
نویسندگان
چکیده
منابع مشابه
Late Thrombolysis in Massive Pulmonary Thromboembolism
Pulmonary thromboembolism (PTE) remains a diagnostic and therapeutic challenge for physicians. Anticoagulation with heparin remains as the cornerstone in its management, reserving thrombolysis for cases with hemodynamic impairment. The later has been associated with haemorrhagic complications and has proved beneficial when initiated within the first 48 hours of PTE; but there is little evidence...
متن کاملThrombolysis in acute pulmonary thromboembolism.
Acute pulmonary embolism (PE) is a common clinical condition with presentations that may vary from asymptomatic subsegmental emboli to massive vascular obstruction and shock with high risk of death. Identifying patients at highest risk for death is critical to select those who would benefit most from thrombolytic therapy. New and evolving clinical prediction models, serum tests, and imaging mod...
متن کاملMassive Pulmonary Thromboembolism and Stroke
A 38-year-old HIV-positive female, recently started on antiretroviral therapy, presented in extremis. She had features suggestive of an HIV-associated cardiomyopathy complicated by the following problems: a four-day-old stroke, extensive deep venous thrombosis, and massive pulmonary embolism. She received intravenous streptokinase with rapid improvement, both haemodynamically and, unexpectedly,...
متن کاملRight lung exclusion in massive pulmonary thromboembolism
1. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brasil. A 37-year-old female patient presented to the emergency department with a 3-week history of dyspnea, hypoxemia, pleuritic chest pain, and lower limb edema. She had no history of comorbidities and had had two normal pregnancies. There was no family history of thrombos...
متن کاملDesmoteplase in acute massive pulmonary thromboembolism.
Alteplase is standard therapy for patients with acute, massive pulmonary embolism. The novel plasminogen activator desmoteplase displays high fibrin specificity and selectivity for fibrinbound plasminogen. In a preclinical model desmoteplase was twice as potent with a shorter lysis time and lower reocclusion rate. We conducted a phase II study comparing 125, 180, and 250 microg/kg bodyweight de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Journal of Anesthesiology
سال: 2012
ISSN: 2164-5531,2164-5558
DOI: 10.4236/ojanes.2012.25055